Shandong Keyuan Pharmaceutical

Shandong Keyuan Pharmaceutical is a prominent Chinese pharmaceutical company focused on the development, manufacturing, and commercialization of chemical Active Pharmaceutical Ingredients (APIs) and finished dosage forms. Established in 2004 and headquartered in Jinan, Shandong, the company operates as a key subsidiary of the Linuo Group and specializes in treatments for chronic conditions, including diabetes, cardiovascular diseases, and psychiatric disorders. Its extensive product portfolio features high-demand drugs such as metformin hydrochloride, gliclazide, and ropivacaine hydrochloride, which are distributed both domestically and to over 50 countries globally. Keyuan also provides comprehensive contract manufacturing (CMO/CDMO) services, leveraging its state-of-the-art GMP-certified facilities to partner with international pharmaceutical leaders. The company's successful IPO on the Shenzhen Stock Exchange in 2023 has further fueled its expansion into innovative R&D and global market penetration.